As of the latest Form 4 filed Jul 1, 2026.
What Sensei Biotherapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
2 different Sensei Biotherapeutics Inc insiders made open-market purchases in the last 30 days. When several insiders buy at once it’s a stronger, harder-to-explain-away signal than a single trade — how to read this.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 27 most recent filings for SNSE.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-07-01 | STEPHENSON BRIAN C Chief Financial Officer | PPurchase | +600.00 | $24.22 | $14.5K | No | Form 4 ↗ |
| 2026-07-01 | 2026-07-01 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +4.40K | $23.40 | $103K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +4.25K | $24.98 | $106K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.64K | $23.88 | $39.1K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.91K | $22.95 | $43.8K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +831.00 | $23.34 | $19.4K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-26 | STEPHENSON BRIAN C Chief Financial Officer | PPurchase | +100.00 | $26.39 | $2.64K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-26 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.36K | $25.55 | $34.7K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-26 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +4.21K | $24.90 | $105K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-26 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +580.00 | $23.61 | $13.7K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +100.00 | $27.77 | $2.78K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +3.40K | $26.98 | $91.7K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +3.00K | $25.98 | $77.9K | No | Form 4 ↗ |
| 2026-06-26 | 2026-06-24 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +2.89K | $25.22 | $72.9K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-23 | STEPHENSON BRIAN C Chief Financial Officer | PPurchase | +425.00 | $25.91 | $11.0K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-23 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.97K | $24.84 | $48.9K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-23 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +6.84K | $24.12 | $165K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | Parikh Anand Kiran President and CEO | MExercise | +8.21K | $1.16 | $9.53K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | Parikh Anand Kiran, President and CEO | MExercise | +45.3K | $1.16 | $52.5K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | Parikh Anand Kiran, President and CEO | PPurchase | +2.81K | $19.76 | $55.4K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | STEPHENSON BRIAN C Chief Financial Officer | PPurchase | +356.00 | $23.95 | $8.53K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +3.33K | $23.28 | $77.5K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.58K | $22.40 | $35.5K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.12K | $20.82 | $23.3K | No | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | STEPHENSON BRIAN C, Chief Financial Officer | PPurchase | +1.80K | $20.23 | $36.4K | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | Hahn Stephen M. Director | CConvert | +44.8K | — | — | No | Form 4 ↗ |
| 2026-06-16 | 2026-06-15 | Parikh Anand Kiran President and CEO | CConvert | +761K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also SNSE’s full analysis or the market-wide insider trading feed. The tabs above jump to SNSE’s other SEC data.
Source: SEC Form 4 filings for SNSE, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.